Vasomedical gets Medicare to review counterpulsation therapy
This article was originally published in Clinica
Medicare has agreed to reconsider its current coverage policy for counterpulsation therapy at the request of device manufacturer Vasomedical. The federal health plan for the elderly and disabled has been paying to treat patients diagnosed with disabling angina since 1999, but now will consider paying to also treat patients with less severe angina or with early or moderate congestive heart failure (CHF) as well.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.